Description

Stryker Corporation: How Are They Bolstering Growth Through Targeted Acquisitions?

Stryker delivered a strong performance in its third quarter of 2024, highlighting robust organic sales growth and strategic acquisitions that complement its diverse product portfolio. The company reported an 11.5% increase in organic sales, demonstrating comprehensive growth across its MedSurg, Neurotechnology, Orthopaedics, and Spine segments. Internal growth was robust in the U.S. and internationally, with both markets performing double digits organically. Stryker’s adjusted EPS grew by 16.7% to $2.87 compared to the same period in the previous year.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!